about
Subacute cutaneous lupus erythematosus induced by nivolumab.Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.Acanthoma planoepitheliale hyperkeratoticum, lesions associated with BRAF inhibitor in metastatic melanoma.Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab.Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.Management of the cutaneous adverse effects of antimelanoma therapy
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cutaneous Complications of Targeted Melanoma Therapy.
@en
type
label
Cutaneous Complications of Targeted Melanoma Therapy.
@en
prefLabel
Cutaneous Complications of Targeted Melanoma Therapy.
@en
P2093
P2860
P1476
Cutaneous Complications of Targeted Melanoma Therapy.
@en
P2093
Bernice Y Kwong
Emily de Golian
Silvina B Pugliese
Susan M Swetter
P2860
P2888
P356
10.1007/S11864-016-0434-0
P577
2016-11-01T00:00:00Z
P6179
1001500697